Phase II Double Blinded, Placebo-Controlled, Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an Anti-IgE mAb
-
Investigator: Jeffrey Bluestone, PhD
Sponsor: Genentech, Inc.
Location(s): United States
Description
no description available